Drug Design, Development and Therapy (Jul 2024)
Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy
Abstract
Sarah-Jane Martin,1,2 Melanie Guenette,1 Jiwon Oh1 1Division of Neurology, Department of Medicine, St Michael’s Hospital, Toronto, Canada; 2University of Glasgow, Glasgow, UKCorrespondence: Jiwon Oh, Email [email protected]: B cells are critical to the pathogenesis of multiple sclerosis (MS), an autoimmune disease of the central nervous system. B cell depletion using anti-CD20 monoclonal antibodies (mAbs) has proven to be an extremely successful treatment strategy, with profound suppression of both clinical and radiological evidence of focal inflammatory disease. Several anti-CD20 mAbs are now licensed for use in MS, with ublituximab being the latest to gain regulatory approval. The unique properties of each of the anti-CD20 mAb may result in nuanced differences in timing, duration and depth of B cell depletion, with the potential for such differences to have a clinical relevance to both drug efficacy and adverse effects. In this review, we summarize the design, development, and current place in MS therapy for ublituximab.Keywords: multiple sclerosis, ublituximab, B-cell therapy, anti-CD20 monoclonal antibody
